X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   ACTAVIS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ACTAVIS
Dec-14
ALKEM LABORATORIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,58918,553-   
Low Rs1,23211,317-   
Sales per share (Unadj.) Rs417.53,340.9-  
Earnings per share (Unadj.) Rs56.3-416.9-  
Cash flow per share (Unadj.) Rs64.7306.5-  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.97,246.3-  
Shares outstanding (eoy) m119.57265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.5 75.6%   
Avg P/E ratio x25.1-35.8 -69.9%  
P/CF ratio (eoy) x21.848.7 44.7%  
Price / Book Value ratio x4.82.1 233.6%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6533,971,215 4.2%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m9,1710-   
Avg. sales/employee Rs ThNM41,127.2-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-5,132.2-  
INCOME DATA
Net Sales Rs m49,915888,347 5.6%  
Other income Rs m1,645-2,217 -74.2%   
Total revenues Rs m51,561886,129 5.8%   
Gross profit Rs m8,482114,121 7.4%  
Depreciation Rs m1,006192,359 0.5%   
Interest Rs m67128,020 2.4%   
Profit before tax Rs m8,451-108,476 -7.8%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,957 0.0%   
Tax Rs m1,606-5,577 -28.8%   
Profit after tax Rs m6,731-110,856 -6.1%  
Gross profit margin %17.012.8 132.3%  
Effective tax rate %19.05.1 369.6%   
Net profit margin %13.5-12.5 -108.1%  
BALANCE SHEET DATA
Current assets Rs m27,062468,045 5.8%   
Current liabilities Rs m15,324341,342 4.5%   
Net working cap to sales %23.514.3 164.9%  
Current ratio x1.81.4 128.8%  
Inventory Days Days6758 114.6%  
Debtors Days Days4166 62.3%  
Net fixed assets Rs m12,610108,476 11.6%   
Share capital Rs m2390-   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,0271,926,791 1.8%   
Long term debt Rs m1,2121,009,676 0.1%   
Total assets Rs m54,3873,531,174 1.5%  
Interest coverage x13.6-2.9 -473.7%   
Debt to equity ratio x00.5 6.6%  
Sales to assets ratio x0.90.3 364.8%   
Return on assets %13.6-2.3 -580.2%  
Return on equity %19.2-5.8 -334.0%  
Return on capital %24.9-3.0 -825.6%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,259152,546 4.8%  
From Investments Rs m1,864-365,255 -0.5%  
From Financial Activity Rs m-9,273205,220 -4.5%  
Net Cashflow Rs m-150-7,488 2.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare ALKEM LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: ALEMBIC PHARMA  UNICHEM LAB  PLETHICO PHARMA  WYETH LTD  FRESENIUS KABI ONCO.  



Today's Market

Indian Indices Trade in Red; US-China Trade War Back On; IPO Buzz and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened flat and ended the day in red. The S&P BSE Midcap Index ended down by 1% while S&P BSE Small Cap Index ended down by 1.3%.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jun 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS